TY  - JOUR

T1  - Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial

JO  - The Lancet Oncology

PY  - 2017/06/01

AU  - Earl HM

AU  - Hiller L

AU  - Howard HC

AU  - Dunn JA

AU  - Young J

AU  - Bowden SJ

AU  - McDermaid M

AU  - Waterhouse AK

AU  - Wilson G

AU  - Agrawal R

AU  - O'Reilly S et al

ED  - 

DO  - DOI: 10.1016/S1470-2045(17)30319-4

VL  - 18

IS  - 6

SP  - 755

EP  - 769

Y2  - 2025/10/10

ER  -